OXBOF (Oxford BioDynamics) Change In Inventory: $0.08 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Oxford BioDynamics Change In Inventory?

Oxford BioDynamics OXBOF Change In Inventory is $0.08 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Oxford BioDynamics's change in inventory for the quarter that ended in Mar. 2026 was $-0.04 Mil. It means Oxford BioDynamics's inventory increased by $0.04 Mil from Sep. 2025 to Mar. 2026 .

Oxford BioDynamics's change in inventory for the fiscal year that ended in Sep. 2025 was $0.17 Mil. It means Oxford BioDynamics's inventory declined by $0.17 Mil from Sep. 2024 to Sep. 2025 .

Oxford BioDynamics's Total Inventories for the quarter that ended in Mar. 2026 was $0.30 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Oxford BioDynamics's Days Inventory for the quarter that ended in Mar. 2026 was 112.67.

Inventory Turnover measures how fast the company turns over its inventory within a year. Oxford BioDynamics's Inventory Turnover for the quarter that ended in Mar. 2026 was 1.62.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Oxford BioDynamics's Inventory-to-Revenue for the quarter that ended in Mar. 2026 was 0.31.

Oxford BioDynamics  (OTCPK:OXBOF) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Oxford BioDynamics's Days Inventory for the quarter that ended in is calculated as:

Days Inventory=Average Total Inventories/Cost of Goods Sold*Days in Period
=0.284/0.46*365 / 2
=112.67

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Oxford BioDynamics's Inventory Turnover for the quarter that ended in Mar. 2026 is calculated as

Inventory Turnover=Cost of Goods Sold / Average Total Inventories
=0.46 / 0.284
=1.62

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Oxford BioDynamics's Inventory to Revenue for the quarter that ended in Mar. 2026 is calculated as

Inventory-to-Revenue=Average Total Inventories / Revenue
=0.284 / 0.916
=0.31

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics Change In Inventory Related Terms

Oxford BioDynamics Change In Inventory Historical Data

* Premium members only.

The historical data trend for Oxford BioDynamics's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxford BioDynamics Change In Inventory Chart

Oxford BioDynamics Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Change In Inventory
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 0.06 0.08 -0.06 0.17

Oxford BioDynamics Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Change In Inventory Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.06 -0.12 0.04 0.13 -0.04

Oxford BioDynamics Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Inventory →
What does a Change In Inventory of $0.08 Mil mean?
Oxford BioDynamics (OXBOF) has a Change In Inventory of $0.08 Mil as of Mar. 2026. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Oxford BioDynamics and its competitors.
Is Oxford BioDynamics' Change In Inventory too high?
Oxford BioDynamics' current Change In Inventory is $0.08 Mil.
How does Oxford BioDynamics' Change In Inventory compare to TMO and DHR?
Oxford BioDynamics' Change In Inventory of $0.08 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Inventory for a Medical Diagnostics & Research company?
A good Change In Inventory depends on the Medical Diagnostics & Research industry context. However, Change In Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Inventory mean?
A high Change In Inventory can signal that a stock is expensive relative to its fundamentals. Change in Inventory is the difference between current-period inventory and past-period inventory. View historical data for Oxford BioDynamics and its competitors. Oxford BioDynamics's current Change In Inventory is $0.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxford BioDynamics stock overvalued right now?
Based on GuruFocus' analysis, Oxford BioDynamics (OXBOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.01, compared to a current price of $0.00 — trading 75% below its estimated fair value. The current Change In Inventory is $0.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Inventory calculated?
Change In Inventory is calculated from a company's financial statements. For Oxford BioDynamics (OXBOF), the current Change In Inventory is $0.08 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxford BioDynamics Business Description

Other Exchanges OBD:UKLMQ:Germany
Address John Smith Drive, 3140 Rowan Place, Oxford Business Park South, Oxford, GBR, OX4 2WB
Oxford BioDynamics PLC is a biotechnology company focused on advancing personalized healthcare through the development and commercialization of precision medicine tests for serious and impactful diseases. The company is engaged in the commercialisation of proprietary molecular diagnostics products and biomarker research and development. It has two commercially available products: the EpiSwitch PSE (EpiSwitch Prostate Cancer Detection Test) and EpiSwitch CiRT (Checkpoint Inhibitor Response Test) blood tests. The company generates revenue from the sales of proprietary products and biomarker research and development. Geographically, it generates the maximum revenue from the USA.